← Back to Laramie

Document Laramie_doc_79489e9104

Full Text

SUBJECT TO CHANGE BASED ON FEDERAL REGULATIONS City Of Laramie Preventive/Wellness Benefits These benefits meet the criteria outlined in the Patient Protection and Affordable Care Act (PPACA) for wellness and preventive benefits. In addition, these benefits meet the definition of comprehensive adult wellness benefits in the Wyoming Health Insurance Code. Benefits, OTHER than those outlined below, will not be covered as a preventive or wellness benefit. When services are provided by Participating providers, benefits will be provided at 100% of the Allowable Charges for Covered Services without regard to any Deductible or Coinsurance that might otherwise apply. When services are provided by Non-participating providers, benefits for Covered Services will be provided subject to the Deductible and Coinsurance provisions of the plan. The following services are covered preventive services: • Well Child Care to the Participant’s 6th Birthday o Birth through 12 months – 7 visits o 13 months through 35 months – 4 visits o 36 months through 72 months – 1 visit per calendar year o Visual impairment under age 5 – 1 visit per calendar year o Immunizations as recommended by the CDC o Congenital hypothyroidism screening under age 1 o Hearing loss screening up to 1 month of age o Phenylketonuria (PKU) screening – once per lifetime ages 0 – 1 years old o Sickle cell disease screening – up to age 1 o Iron deficiency anemia prevention for children at risk 6 to 12 months • Participants Age 6 and Older: o Routine physical examination (office visit) – 1 per calendar year o Adult aortic aneurysm screening for male participants age 65 and older – lifetime maximum of 1 screening o Alcohol misuse screening and behavioral counseling intervention – 1 visit per calendar year o Asymtomatic bacteriuria screening – pregnant women only o Hepatitis B virus screening – pregnant women only o Rh incompatibility screening – pregnant women only o Lipid disorders screening once every 5 calendar years o Osteoporosis screening once every 2 calendar years – females age 60 and older o Iron deficiency anemia screening – pregnant women only ---PAGE BREAK--- SUBJECT TO CHANGE BASED ON FEDERAL REGULATIONS o Sexually transmitted disease (STD) screening: § Chlamydial infection screening – women only § Gonorrhea infection screening – women only § Syphilis infection screening – women and men o Diagnostic screening procedure for HIV testing for at risk participants and pregnant women o Type 2 diabetes mellitus screening o Immunizations as recommended by the CDC o Colorectal cancer screening for members age 50 through 75: § Fecal occult blood test – 1 per calendar year § Colonoscopy (including related services) – 1 every 10 years OR § Sigmoidoscopy (including related services) – 1 every 5 years o Cervical cancer screening and related office visit – 1 per calendar year o PSA test – 1 per calendar year for subscriber and spouse only (not covered under PPACA) o Mammogram screening – 1 per calendar year for subscriber and spouse only (only covered 1 per calendar year for subscriber and spouse for ages 40+ under PPACA) o Tobacco cessation counseling – 8 visits per calendar year • Prescription Drugs* - must be filled as a prescription and submitted through the prescriptions drug card program o Aspirin – limited to 81 mg only § Ages 45 – 79 for males § Ages 55 – 79 for females o Folic acid (non prenatal) – limited to 0.4 – 0.8 mg only § Women only o Oral fluoride – over the counter or prescription strength § Children age 6 months – 6 years when sufficient fluoride is lacking in available drinking water o Iron supplements § Children age 6 – 12 months and at risk for anemia o Tobacco cessation – up to a 180 day supply § Non-nicotine replacement therapy (pills) § Over the counter nicotine replacement therapy (lozenges, patch and gum) § Prescription nicotine replacement therapy (nasal spray and inhalers) *Brand Drugs – If the participant chooses a brand drug when a generic drug is available, the participant must pay the difference in cost between the brand and the generic drug.